vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and HANMI FINANCIAL CORP (HAFC). Click either name above to swap in a different company.
HANMI FINANCIAL CORP is the larger business by last-quarter revenue ($71.2M vs $62.1M, roughly 1.1× Cytek Biosciences, Inc.). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs -70.9%, a 100.8% gap on every dollar of revenue. On growth, HANMI FINANCIAL CORP posted the faster year-over-year revenue change (17.1% vs 8.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 10.4%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
CTKB vs HAFC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $71.2M |
| Net Profit | $-44.1M | $21.2M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 29.8% |
| Net Margin | -70.9% | 29.8% |
| Revenue YoY | 8.1% | 17.1% |
| Net Profit YoY | -557.1% | 20.0% |
| EPS (diluted) | — | $0.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $71.2M | ||
| Q3 25 | $52.3M | $71.0M | ||
| Q2 25 | $45.6M | $65.2M | ||
| Q1 25 | $41.5M | $62.8M | ||
| Q4 24 | $57.5M | $60.8M | ||
| Q3 24 | $51.5M | $58.5M | ||
| Q2 24 | $46.6M | $56.7M | ||
| Q1 24 | $44.9M | $58.4M |
| Q4 25 | $-44.1M | $21.2M | ||
| Q3 25 | $-5.5M | $22.1M | ||
| Q2 25 | $-5.6M | $15.1M | ||
| Q1 25 | $-11.4M | $17.7M | ||
| Q4 24 | $9.6M | $17.7M | ||
| Q3 24 | $941.0K | $14.9M | ||
| Q2 24 | $-10.4M | $14.5M | ||
| Q1 24 | $-6.2M | $15.2M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 29.8% | ||
| Q3 25 | -17.6% | 31.1% | ||
| Q2 25 | -23.3% | 23.2% | ||
| Q1 25 | -36.1% | 28.1% | ||
| Q4 24 | 5.2% | 29.1% | ||
| Q3 24 | -8.2% | 25.5% | ||
| Q2 24 | -18.3% | 25.5% | ||
| Q1 24 | -23.9% | 26.0% |
| Q4 25 | -70.9% | 29.8% | ||
| Q3 25 | -10.5% | 31.1% | ||
| Q2 25 | -12.2% | 23.2% | ||
| Q1 25 | -27.5% | 28.1% | ||
| Q4 24 | 16.8% | 29.1% | ||
| Q3 24 | 1.8% | 25.5% | ||
| Q2 24 | -22.4% | 25.5% | ||
| Q1 24 | -13.8% | 26.0% |
| Q4 25 | — | $0.70 | ||
| Q3 25 | — | $0.73 | ||
| Q2 25 | — | $0.50 | ||
| Q1 25 | — | $0.58 | ||
| Q4 24 | — | $0.58 | ||
| Q3 24 | — | $0.49 | ||
| Q2 24 | — | $0.48 | ||
| Q1 24 | — | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $796.4M |
| Total Assets | $461.5M | $7.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | — | ||
| Q3 25 | $93.3M | — | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | — | ||
| Q3 24 | $162.3M | — | ||
| Q2 24 | $177.9M | — | ||
| Q1 24 | $168.8M | — |
| Q4 25 | $341.7M | $796.4M | ||
| Q3 25 | $378.6M | $779.5M | ||
| Q2 25 | $377.6M | $762.8M | ||
| Q1 25 | $379.6M | $751.5M | ||
| Q4 24 | $395.7M | $732.2M | ||
| Q3 24 | $385.5M | $736.7M | ||
| Q2 24 | $389.1M | $707.1M | ||
| Q1 24 | $392.6M | $703.1M |
| Q4 25 | $461.5M | $7.9B | ||
| Q3 25 | $494.9M | $7.9B | ||
| Q2 25 | $493.3M | $7.9B | ||
| Q1 25 | $482.6M | $7.7B | ||
| Q4 24 | $499.5M | $7.7B | ||
| Q3 24 | $491.2M | $7.7B | ||
| Q2 24 | $483.7M | $7.6B | ||
| Q1 24 | $492.1M | $7.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $206.0M |
| Free Cash FlowOCF − Capex | $-1.8M | $203.7M |
| FCF MarginFCF / Revenue | -2.9% | 286.2% |
| Capex IntensityCapex / Revenue | 1.6% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 9.70× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $356.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $206.0M | ||
| Q3 25 | $-3.9M | $146.9M | ||
| Q2 25 | $108.0K | $-19.0M | ||
| Q1 25 | $-125.0K | $25.8M | ||
| Q4 24 | $2.0M | $52.6M | ||
| Q3 24 | $13.2M | $6.7M | ||
| Q2 24 | $6.2M | $2.1M | ||
| Q1 24 | $4.0M | $30.0M |
| Q4 25 | $-1.8M | $203.7M | ||
| Q3 25 | $-4.6M | $146.4M | ||
| Q2 25 | $-1.5M | $-19.6M | ||
| Q1 25 | $-974.0K | $25.6M | ||
| Q4 24 | $1.1M | $49.9M | ||
| Q3 24 | $12.2M | $6.5M | ||
| Q2 24 | $5.2M | $1.3M | ||
| Q1 24 | $3.4M | $29.2M |
| Q4 25 | -2.9% | 286.2% | ||
| Q3 25 | -8.7% | 206.3% | ||
| Q2 25 | -3.2% | -30.0% | ||
| Q1 25 | -2.3% | 40.7% | ||
| Q4 24 | 1.9% | 82.1% | ||
| Q3 24 | 23.7% | 11.1% | ||
| Q2 24 | 11.0% | 2.3% | ||
| Q1 24 | 7.6% | 50.0% |
| Q4 25 | 1.6% | 3.2% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 3.5% | 0.9% | ||
| Q1 25 | 2.0% | 0.4% | ||
| Q4 24 | 1.6% | 4.3% | ||
| Q3 24 | 2.0% | 0.4% | ||
| Q2 24 | 2.3% | 1.4% | ||
| Q1 24 | 1.3% | 1.4% |
| Q4 25 | — | 9.70× | ||
| Q3 25 | — | 6.66× | ||
| Q2 25 | — | -1.26× | ||
| Q1 25 | — | 1.46× | ||
| Q4 24 | 0.21× | 2.97× | ||
| Q3 24 | 14.05× | 0.45× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 1.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
HAFC
Segment breakdown not available.
